

New Zealand Datasheet

Name of Medicine

POSALFILIN

Podophyllum resin BP 20% and salicylic acid BP 25%

Presentation

POSALFILIN Ointment is a dark brown fatty base ointment

Uses

Actions

POSALFILIN contains salicylic acid, which works as a desquamating agent. Salicylic acid produces desquamation of the horny layer covering the wart, allowing the podophyllum resin to penetrate the wart, acting as an antimitotic agent causing destruction of the tissue at the site of application.

Pharmacokinetics

Not applicable

Indications

Treatment of plantar warts on the feet

Dosage and Administration

Mask the skin around the wart either by applying clear nail varnish or by cutting a hole in a plaster, leaving the wart exposed.

Apply the paint or ointment to the exposed wart, using a minimum amount and avoiding normal skin. Cover the wart with a non-absorbent waterproof plaster.

Reapply POSALFILIN Ointment and dressing every two days.

When the wart appears spongy, stop treatment and leave wart uncovered. Wart should fall off after one to two days. If not, repeat procedure.

Treatment can be applied by the patient at home. Detailed usage instructions are provided in the Consumer Medicine Leaflet included in the pack.

Contraindications

Do not use in patients who are diabetic, or have impaired circulation. POSALFILIN preparations should not be used for the treatment of ano-genital warts (condylomata acuminata), nor be applied to moles, birthmarks or unusual skin growths.

Do not use in pregnant women or infants [see Use in Pregnancy and Use in Children]

Warnings and Precautions

POSALFILIN should preferably be used under medical supervision. Patients should be advised that POSALFILIN is caustic to healthy skin and mucous membranes and should not be applied near the eyes or the ano-genital area. POSALFILIN is not to be used over large areas, for prolonged periods, or on friable, bleeding or recently biopsied warts, as this increases the risk of systemic toxicity.

If pain or inflammation occurs during treatment, application should be discontinued until inflammation has subsided.

Use in Pregnancy

Due to the podophyllum content in POSALFILIN, do not use in pregnant women.

Use in Children

Do not use on infants or young children except on medical advice.

Adverse Effects

Careless application may lead to damage to the dermis and can burn healthy skin.

Interactions

None

Overdosage

If POSALFILIN is swallowed, contact a doctor or the Poisons Information Centre 0800 POISON or 0800 764766. DO NOT INDUCE VOMITING. Symptoms of overdosage when ingested may include hyperventilation, fever, restlessness, ketosis, respiratory alkalosis and metabolic acidosis. If ingested, POSALFILIN should be removed from the stomach by lavage. Any remaining POSALFILIN may be absorbed by activated charcoal.

Pharmaceutical Precautions

Store below 25°C

Medicine Classification

Pharmacist Only Medicine

Package Quantities

10g tube

Further Information

Excipients

Yellow soft paraffin

Liquid paraffin

POSALFILIN and Norgine are trademarks.

Name and Address

Sponsor:

CARSL Consulting

PO Box 480

Pukekohe

Ph (09) 238 3447

Fax (09) 238 9239

For Norgine Pty Limited

Distributor:

Pharmacy Retailing (NZ) Ltd

Trading as Healthcare Logistics

58 Richard Pearse Drive

Airport Oaks

PO Box 62-027

Mt Wellington

Auckland

Telephone: (09) 918 5100

Fax: (09) 918 5101

Date of Preparation
29 June 2006